Moreover, solid evidence demonstrates that EGFR inhibitors make the growth and survival of GBM cells dependent on PDGFRβ signaling, the reason why being in order to improve the therapeutic effect of CL4. This evidence concerns the gene PDGFRB and glioblastoma.